INS NYC 2024 Program

Poster	Poster Session 09 Program Schedule 02/16/2024 03:30 pm - 04:45 pm Room: Shubert Complex (Posters 1-60) Poster Session 09: Epilepsy \| Oncology \| MS \| Infectious Disease Final Abstract #21 Executive Complaints Following COVID-19: A Cross-Sectional Population Study from the Norwegian COVID-19 Cohort Study Sofie Buer, Department of Research, Lovsenberg Diaconal Hospital, Oslo, Norway Bjørn Hagen, Department of Research, Lovisenberg Diaconal Hospital, Oslo, Norway Anders Nygaard, Department of Microbiology, Oslo University Hospital, Oslo, Norway Ragnhild Bø, Department of Psychology, University of Oslo, Oslo, Norway Merete Ellingjord-Dale, Department of Microbiology, Oslo University Hospital, Oslo, Norway Mette Istre, Department of Microbiology, Oslo University Hospital, Oslo, Norway Sonja Brunvoll, Department of Microbiology, Oslo University Hospital, Oslo, Norway Anners Lerdal, Faculty of Medicine, University of Oslo, Oslo, Norway Nils Inge Landrø, Department of Psychology, University of Oslo, Oslo, Norway Arne Søraas, Department of Microbiology, Oslo University Hospital, Oslo, Norway Jan Stubberud, Department of Psychology, University of Oslo, Oslo, Norway Category: Executive Functions/Frontal Lobes Keyword 1: cognitive functioning Keyword 2: cognitive control Keyword 3: memory complaints Objective: Despite frequent reports of deficits in executive functions (EFs) following COVID-19, few studies have investigated this using standardized measures that can differentiate between aspects of EF. By using the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A), we explored self-reported executive dysfunction in a population-based sample with confirmed SARS-CoV-2 positive and negative status. Specifically, we examined scores above the clinical cut-off according to US norms. Participants and Methods: The current study is a population-based cross-sectional study. We used data collected from the Norwegian COVID-19 Cohort study (clinical.trials.gov identifier: NTC04320732). Participants (aged 18-65) completed the BRIEF-A electronically in April 2021, where 4183 were PCR-confirmed SARS-CoV-2-positive and 3919 negative. Raw scores were converted into standardized T-scores, including the Global executive composite score, the Metacognitive index, and the Behavioral index, in addition to nine clinical subscales. Unadjusted bivariate two-group comparisons were performed between the SARS-CoV-2-positive and negative. Results: A Chi-Square test of the number of persons scoring above the clinical cut-off according to US norms revealed statistically significant differences (p< .05) between negative SARS-CoV-2 and positive SARS-CoV-2 across all scores, with a higher prevalence of scoring above cut-off in the group with positive SARS-CoV-2 status. Specifically, 225 (5.7%) participants with negative SARS-CoV-2 status scored above the clinical cut-off on the Global executive composite, compared to 383 (9.2%) with positive SARS-CoV-2 status. Furthermore, 503 (12%) participants with positive SARS-CoV-2 status scored above the cut-off on the Metacognitive index, compared to 281 (7.2) % in the SARS-CoV-2 negative group. At the subdomain level, working memory was the most notably affected domain with a difference of 8%. Conclusions: These preliminary findings shed light on potential functional problems experienced in daily life following COVID-19 and may guide further development of targeted interventions addressing executive dysfunction following COVID-19.

Poster

02/16/2024
03:30 pm - 04:45 pm
Room: Shubert Complex (Posters 1-60)

Poster Session 09: Epilepsy | Oncology | MS | Infectious Disease

Final Abstract #21

Executive Complaints Following COVID-19: A Cross-Sectional Population Study from the Norwegian COVID-19 Cohort Study

Sofie Buer, Department of Research, Lovsenberg Diaconal Hospital, Oslo, Norway
Bjørn Hagen, Department of Research, Lovisenberg Diaconal Hospital, Oslo, Norway
Anders Nygaard, Department of Microbiology, Oslo University Hospital, Oslo, Norway
Ragnhild Bø, Department of Psychology, University of Oslo, Oslo, Norway
Merete Ellingjord-Dale, Department of Microbiology, Oslo University Hospital, Oslo, Norway
Mette Istre, Department of Microbiology, Oslo University Hospital, Oslo, Norway
Sonja Brunvoll, Department of Microbiology, Oslo University Hospital, Oslo, Norway
Anners Lerdal, Faculty of Medicine, University of Oslo, Oslo, Norway
Nils Inge Landrø, Department of Psychology, University of Oslo, Oslo, Norway
Arne Søraas, Department of Microbiology, Oslo University Hospital, Oslo, Norway
Jan Stubberud, Department of Psychology, University of Oslo, Oslo, Norway

Category: Executive Functions/Frontal Lobes

Keyword 1: cognitive functioning
Keyword 2: cognitive control
Keyword 3: memory complaints

Objective:

Despite frequent reports of deficits in executive functions (EFs) following COVID-19, few studies have investigated this using standardized measures that can differentiate between aspects of EF.

By using the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A),

we explored self-reported executive dysfunction in a population-based sample with confirmed SARS-CoV-2 positive and negative status. Specifically, we examined scores above the clinical cut-off according to US norms.

Participants and Methods:

The current study is a population-based cross-sectional study. We used data collected from

the Norwegian COVID-19 Cohort study (clinical.trials.gov identifier: NTC04320732). Participants (aged 18-65) completed the BRIEF-A electronically in April 2021, where 4183 were PCR-confirmed SARS-CoV-2-positive and 3919 negative. Raw scores were converted into standardized T-scores, including the Global executive composite score, the Metacognitive index, and the Behavioral index, in addition to nine clinical subscales. Unadjusted bivariate two-group comparisons were performed between the SARS-CoV-2-positive and negative.

Results:

A Chi-Square test of the number of persons scoring above the clinical cut-off according to US norms revealed statistically significant differences (p< .05) between negative SARS-CoV-2 and positive SARS-CoV-2 across all scores, with a higher prevalence of scoring above cut-off in the group with positive SARS-CoV-2 status. Specifically, 225 (5.7%) participants with negative SARS-CoV-2 status scored above the clinical cut-off on the Global executive composite, compared to 383 (9.2%) with positive SARS-CoV-2 status. Furthermore, 503 (12%) participants with positive SARS-CoV-2 status scored above the cut-off on the Metacognitive index, compared to 281 (7.2) % in the SARS-CoV-2 negative group. At the subdomain level, working memory was the most notably affected domain with a difference of 8%.

Conclusions:

These preliminary findings shed light on potential functional problems experienced in daily life following COVID-19 and may guide further development of targeted interventions addressing executive dysfunction following COVID-19.